AVN 12% Strides Linked TO Apple, Inc.

AVANIR Pharmaceuticals (AMEX:AVN) will host a conference call on Wednesday, July 13th, at 4:30 p.m. Eastern to discuss the global partnership with AstraZeneca and the further development of AVANIR's Reverse Cholesterol Transport enhancing compounds for the treatment of cardiovascular disease. Management will also review recently announced corporate milestones, such as the submission of the Company's New Drug Application for Neurodex(TM) in the treatment of pseudobulbar affect, and the initiation of a Phase III clinical trial for neuropathic pain. The conference call will be webcast live through AVANIR's corporate website at http://www.avanir.com. The call will be hosted by Charles Mathews, Chairman of the Board, and will include James Berg, Vice President, Clinical and Regulatory Affairs; Marty Emanuele, Ph.D., Vice President, Business Development; and Jagadish Sircar, Ph.D., Vice President, Drug Development. It is recommended that you go to AVANIR's website at least 10 minutes in advance of the webcast to download any applicable software. For those who cannot listen to the live broadcast, the online replay will be available for 90 days, and a phone replay will be available for 7 days by dialing 866-225-2976 (domestic) and 703-639-1127 (international) and entering the passcode 738943. AVANIR Pharmaceuticals is a pharmaceutical company focused on developing and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. AVANIR recently submitted to the FDA the last modules of its "rolling" new drug application for Neurodex(TM) for the treatment of pseudobulbar affect. Additionally, AVANIR has initiated a double-blind, placebo-controlled, multi-center, Phase 3 clinical trial of Neurodex(TM) in patients with diabetic neuropathic pain. Recently, AVANIR partnered its preclinical research and development program for inflammatory disease with Novartis and its preclinical cardiovascular program with AstraZeneca. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com. Except for the historical information presented herein, matters discussed in this press release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words like "estimate," "anticipate," "believe," "intend," "plan," or "expect" or similar statements are forward-looking statements. Forward-looking statements include, but are not limited to, risks associated with the FDA's review of the Company's new drug application for Neurodex, regulatory decisions by the FDA for the Company's drug candidates, milestones, and royalties earned from licensees, and results of clinical trials or product development efforts, as well as risks described in the Company's most recent Annual Report on Form 10-K and in subsequent quarterly reports on Form 10-Q and from time-to-time in other publicly available information regarding the Company. Research findings are not always supportable by evidence obtained from subsequent clinical trials, and the Company can make no assurances that clinical trials will yield positive results. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are often unpredictable and outside the influence and/or control of the company. The Company disclaims any intent or obligation to update these forward-looking statements.